Media

Media contact

Media library

Fast facts

Page last modified 11 January 2021

Compliance Hotline Report Adverse Drug Reaction

You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.

Choose region and then country

Other Lundbeck sites

Global contacts

Media

Welcome to the media section

Latest releases

Rigshospitalet and Lundbeck announce partnership to find new ways to treat brain diseases

Adjusted Supplementary Information to the Annual Report 2019

Lundbeck announces European Medicines Agency acceptance of marketing authorization application for eptinezumab for the prevention of migraine

Lundbeck is ranked as one of the world’s leading companies for climate efforts

The Danish Business Authority (“Erhvervsstyrelsen”) requires Lundbeck to conduct a new impairment test for 2017 leading to a reversal of an impairment loss on Rexulti (brexpiprazole)

Media contact

General press enquiries, please call +45 3643 4000

Media library

Access visual aids for stories about Lundbeck

Fast facts

Get a quick overview of Lundbeck and our business